Author: Nakajima, Yukiko; Ogai, Asuca; Furukawa, Karin; Arai, Ryosuke; Anan, Ryusuke; Nakano, Yasushi; Kurihara, Yuko; Shimizu, Hideaki; Misaki, Takako; Okabe, Nobuhiko
Title: Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient Cord-id: njgbom98 Document date: 2020_12_4
ID: njgbom98
Snippet: The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4(+)T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained pos
Document: The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4(+)T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients.
Search related documents:
Co phrase search for related documents- active virus and lung present: 1
- admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- admission day and lung present: 1, 2
- lopinavir ritonavir and lung present: 1, 2
Co phrase search for related documents, hyperlinks ordered by date